{{cart_num}}
My CartCAS：157810-81-6
Storage：Powder:2-8℃，2 years;Insolvent(Mother Liquid):-20℃，6 months;-80℃，1 year
Purity：≥98%
Appearance：White to off-white Solid
Qty：
Size：
| CAS | 157810-81-6 |
| Name | Indinavir Sulfate |
| Molecular Formula | C36H49N5O8S |
| Molecular Weight | 711.87 |
| Solubility | Soluble in Water/DMSO(Need ultrasonic) |
| Purity | ≥98% |
| Appearance | White to off-white Solid |
| Storage | Powder:2-8℃，2 years;Insolvent(Mother Liquid):-20℃，6 months;-80℃，1 year |
| MDL | MFCD00920346 |
| SMILES | CC(C)(C)NC(=O)C1CN(CCN1CC(CC(CC2=CC=CC=C2)C(=O)NC3C(CC4=CC=CC=C34)O)O)CC5=CN=CC =C5.OS(=O)(=O)O |
| InChIKey | NUBQKPWHXMGDLP-BDEHJDMKSA-N |
| InChI | InChI=1S/C36H47N5O4.H2O4S/c1-36(2，3)39-35(45)31-24-40(22-26-12-9-15-37-21-26)16-17-41( 31)23-29(42)19-28(18-25-10-5-4-6-11-25)34(44)38-33-30-14-8-7-13-27(30) 20-32(33)43;1-5(2，3)4/h4-15，21，28-29，31-33，42-43H，16-20，22-24H2，1-3H3，(H ，38，44)(H，39，45);(H2，1，2，3，4)/t28-，29+，31+，32-，33+;/m1./s1 |
| PubChem CID | 5462355 |
| Target Point | HIV |
| Passage | Anti-infection |
| Background | It is a potent and specific HIV-1 protease inhibitor, widely used in AIDS research. |
| Biological Activity | Indinavir Sulfate 是一种口服活性和选择性 HIV-1 蛋白酶抑制剂，对 PR 的 Ki 值为 0.54 nM。通过抑制 MMPs-2 的水解活化、抗血管生成和诱导细胞凋亡而具有抗癌活性。还是一种 SARS-CoV 3CLpro 抑制剂[1-4]。 |
| In Vitro | 茚地那韦会干扰原代细胞的细胞周期进程，CD3 单克隆抗体刺激的 PBMC 培养物细胞周期停滞在 G0/G1 期，间接延长细胞存活时间。[1]与对照组相比，用硫酸茚地那韦治疗的Huh7 和 SK-HEP-1 肝癌细胞系侵入体外细胞外基质的能力都有所下降(P = 0，001)。茚地那韦还能抑制基质金属蛋白酶-2的蛋白水解活化，但对细胞增殖没有影响。[2] |
| In Vivo | 硫酸茚地那韦治疗(70 mg/kg；ig；每天一次，持续 3 周)还能延缓裸鼠体内肿瘤的生长。[2] |
| Data Literature Source | [1]. Chavan S，et al. The HIV protease inhibitor Indinavir inhibits cell-cycle progression in vitro in lymphocytes of HIV-infected and uninfected individuals. Blood. 2001 Jul 15;98(2):383-9. [2]. Esposito V，et al. Evaluation of antitumoral properties of the protease inhibitor indinavir in a murine model of hepatocarcinoma. Clin Cancer Res. 2006 Apr 15;12(8):2634-9. [3]. Liu F，et al. Kinetic，stability，and structural changes in high-resolution crystal structures of HIV-1 protease with drug-resistant mutations L24I，I50V，and G73S. J Mol Biol. 2005 Dec 9;354(4):789-800. [4]. Hall DC Jr，et al. A search for medications to treat COVID-19 via in silico molecular docking models of the SARS-CoV-2 spike glycoprotein and 3CL protease. Travel Med Infect Dis. 2020 May-Jun;35:101646. |
| Unit | Bottle |
| Specification | 50mg 100mg |
Remark：These protocols are for reference only. Solarbio does not independently validate these methods.
Note：
1. The products are all for scientific research use only. Do not use it for medical, clinical diagnosis or treatment, food and cosmetics, etc. Do not store them in ordinary residential areas.
2. For your safety and health, please wear laboratory clothes, disposable gloves and masks.
3. The experimental results may be affected by many factors, after-sale service is limited to the product itself and does not involve other compensation.
Manual Download
